Intuitive Surgical, Inc. (NASDAQ:ISRG) Short Interest Update

Intuitive Surgical, Inc. (NASDAQ:ISRG) saw a significant growth in short interest in May. As of May 31st, there was short interest totalling 3,850,000 shares, a growth of 5.5% from the May 15th total of 3,650,000 shares. Based on an average daily trading volume, of 1,370,000 shares, the short-interest ratio is presently 2.8 days.

Intuitive Surgical Stock Performance

Shares of ISRG stock traded up $2.62 on Tuesday, reaching $432.62. The stock had a trading volume of 131,654 shares, compared to its average volume of 1,487,810. Intuitive Surgical has a 1 year low of $254.85 and a 1 year high of $433.79. The stock has a market cap of $153.45 billion, a P/E ratio of 77.62, a price-to-earnings-growth ratio of 5.50 and a beta of 1.39. The company has a 50 day simple moving average of $393.56 and a 200 day simple moving average of $375.72.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period last year, the firm posted $1.00 earnings per share. On average, equities research analysts anticipate that Intuitive Surgical will post 4.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Mark Brosius sold 175 shares of Intuitive Surgical stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the completion of the sale, the senior vice president now owns 883 shares in the company, valued at approximately $343,628.28. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, SVP Mark Brosius sold 175 shares of Intuitive Surgical stock in a transaction on Monday, May 13th. The shares were sold at an average price of $389.16, for a total transaction of $68,103.00. Following the completion of the sale, the senior vice president now directly owns 883 shares of the company’s stock, valued at approximately $343,628.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Robert Desantis sold 1,498 shares of the stock in a transaction on Friday, April 26th. The shares were sold at an average price of $369.92, for a total value of $554,140.16. Following the completion of the transaction, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,037,149.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,956 shares of company stock worth $6,927,011. Corporate insiders own 0.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Objective Capital Management LLC lifted its position in Intuitive Surgical by 11.8% during the first quarter. Objective Capital Management LLC now owns 728 shares of the medical equipment provider’s stock valued at $291,000 after purchasing an additional 77 shares in the last quarter. Cambridge Trust Co. increased its holdings in Intuitive Surgical by 1,093.8% in the 1st quarter. Cambridge Trust Co. now owns 764 shares of the medical equipment provider’s stock worth $305,000 after acquiring an additional 700 shares in the last quarter. Cetera Advisor Networks LLC raised its stake in Intuitive Surgical by 1.6% during the 1st quarter. Cetera Advisor Networks LLC now owns 35,853 shares of the medical equipment provider’s stock worth $14,309,000 after acquiring an additional 568 shares during the period. Cetera Advisors LLC lifted its holdings in Intuitive Surgical by 152.2% during the first quarter. Cetera Advisors LLC now owns 18,037 shares of the medical equipment provider’s stock valued at $7,198,000 after purchasing an additional 10,885 shares in the last quarter. Finally, Cetera Investment Advisers boosted its position in shares of Intuitive Surgical by 190.8% in the first quarter. Cetera Investment Advisers now owns 67,619 shares of the medical equipment provider’s stock worth $26,986,000 after purchasing an additional 44,370 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on ISRG. BTIG Research increased their price target on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Piper Sandler lifted their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. Citigroup raised their price objective on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Stifel Nicolaus boosted their target price on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, Robert W. Baird reduced their price target on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research report on Friday, April 19th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $403.67.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.